{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/advantage-early-and-frequent-regulatory-interactions#webpage",
"url": "https://www.fortrea.com/insights/advantage-early-and-frequent-regulatory-interactions",
"name": "The advantage of early and frequent regulatory interactions",
"description": "This Fortrea white paper explores regulatory strategy considerations for advanced therapies and the evolving regulatory environment affecting cell and gene therapy development programs. The content focuses on regulatory interactions, advanced therapy regulatory planning, clinical trial design considerations, chemistry manufacturing and controls (CMC) strategy, and long-term follow-up planning across advanced therapy development programs. The white paper highlights the importance of early and frequent engagement with regulators to support clinical development planning, assess expedited regulatory pathways, and address regulatory considerations associated with advanced therapies. Fortrea discusses approaches related to flexible clinical trial design, CMC planning, nonclinical data requirements, diversity considerations in pivotal clinical trials, and regulatory preparation throughout advanced therapy development. By integrating regulatory strategy with clinical development planning and evolving regulatory guidance, the white paper provides insights into navigating regulatory considerations for advanced therapies and cell and gene therapy development programs."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "The advantage of early and frequent regulatory interactions",
"item": "https://www.fortrea.com/insights/advantage-early-and-frequent-regulatory-interactions"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/advantage-early-and-frequent-regulatory-interactions#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/advantage-early-and-frequent-regulatory-interactions#webpage"
},
"headline": "Advanced Therapy Regulatory Strategy for Cell and Gene Therapy Development | Fortrea White Paper",
"description": "This Fortrea white paper explores regulatory strategy considerations for advanced therapies and the evolving regulatory environment affecting cell and gene therapy development programs. The content focuses on regulatory interactions, advanced therapy regulatory planning, clinical trial design considerations, chemistry manufacturing and controls (CMC) strategy, and long-term follow-up planning across advanced therapy development programs. The white paper highlights the importance of early and frequent engagement with regulators to support clinical development planning, assess expedited regulatory pathways, and address regulatory considerations associated with advanced therapies. Fortrea discusses approaches related to flexible clinical trial design, CMC planning, nonclinical data requirements, diversity considerations in pivotal clinical trials, and regulatory preparation throughout advanced therapy development. By integrating regulatory strategy with clinical development planning and evolving regulatory guidance, the white paper provides insights into navigating regulatory considerations for advanced therapies and cell and gene therapy development programs.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-11-05",
"dateModified": "2025-11-05",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-11/regulatory-strategy-considerations-for-advanced-therapies.pdf",
"encodingFormat": "application/pdf"
}
}
]
}